Vicarious Surgical Receives Continued Listing Standard Notice from the NYSE
Vicarious Surgical (NYSE: RBOT) has received a notice from the NYSE on April 10, 2025, indicating non-compliance with continued listing standards. The company failed to maintain both a 30-day average market capitalization and stockholders' equity above $50 million, with market cap averaging approximately $47.4 million.
The company has 45 days to submit a compliance plan to the NYSE, detailing actions to meet requirements within an 18-month cure period. During this time, RBOT stock will continue trading with a '.BC' (below criteria) designation. If the plan is not submitted timely or accepted, NYSE will initiate delisting proceedings.
The notice does not affect daily operations or SEC reporting obligations. The company is evaluating options to regain compliance with NYSE listing standards.
Vicarious Surgical (NYSE: RBOT) ha ricevuto una comunicazione dalla NYSE il 10 aprile 2025, che indica la non conformità agli standard di quotazione continuativa. L'azienda non è riuscita a mantenere sia una capitalizzazione di mercato media a 30 giorni che un patrimonio netto degli azionisti superiore a 50 milioni di dollari, con una capitalizzazione di mercato che media circa 47,4 milioni di dollari.
L'azienda ha 45 giorni per presentare un piano di conformità alla NYSE, dettagliando le azioni per soddisfare i requisiti entro un periodo di cura di 18 mesi. Durante questo periodo, le azioni RBOT continueranno a essere scambiate con una designazione '.BC' (sotto i criteri). Se il piano non viene presentato in tempo o non viene accettato, la NYSE avvierà le procedure di delisting.
La comunicazione non influisce sulle operazioni quotidiane o sugli obblighi di reporting SEC. L'azienda sta valutando opzioni per ripristinare la conformità agli standard di quotazione della NYSE.
Vicarious Surgical (NYSE: RBOT) ha recibido un aviso de la NYSE el 10 de abril de 2025, indicando el incumplimiento de los estándares de cotización continua. La empresa no logró mantener tanto una capitalización de mercado promedio de 30 días como un patrimonio neto de los accionistas por encima de los 50 millones de dólares, con una capitalización de mercado que promedia aproximadamente 47,4 millones de dólares.
La empresa tiene 45 días para presentar un plan de cumplimiento a la NYSE, detallando las acciones para cumplir con los requisitos dentro de un período de corrección de 18 meses. Durante este tiempo, las acciones de RBOT continuarán negociándose con una designación '.BC' (por debajo de los criterios). Si el plan no se presenta a tiempo o no es aceptado, la NYSE iniciará procedimientos de deslistado.
El aviso no afecta las operaciones diarias ni las obligaciones de reporte ante la SEC. La empresa está evaluando opciones para recuperar la conformidad con los estándares de cotización de la NYSE.
Vicarious Surgical (NYSE: RBOT)는 2025년 4월 10일 NYSE로부터 지속적 상장 기준 미준수에 대한 통지를 받았습니다. 회사는 30일 평균 시가총액과 주주 자본이 5천만 달러 이상을 유지하지 못했으며, 시가총액은 약 4천740만 달러로 평균되었습니다.
회사는 45일 이내에 NYSE에 준수 계획을 제출해야 하며, 18개월 치료 기간 내에 요구 사항을 충족하기 위한 조치를 상세히 설명해야 합니다. 이 기간 동안 RBOT 주식은 '.BC' (기준 미달) 표시로 계속 거래됩니다. 계획이 제때 제출되지 않거나 수락되지 않으면 NYSE는 상장 폐지 절차를 시작할 것입니다.
이 통지는 일상적인 운영이나 SEC 보고 의무에 영향을 미치지 않습니다. 회사는 NYSE 상장 기준을 회복하기 위한 옵션을 평가하고 있습니다.
Vicarious Surgical (NYSE: RBOT) a reçu un avis de la NYSE le 10 avril 2025, indiquant un non-respect des normes de cotation continue. L'entreprise n'a pas réussi à maintenir à la fois une capitalisation boursière moyenne sur 30 jours et des capitaux propres des actionnaires supérieurs à 50 millions de dollars, la capitalisation boursière étant d'environ 47,4 millions de dollars.
L'entreprise dispose de 45 jours pour soumettre un plan de conformité à la NYSE, détaillant les actions à entreprendre pour répondre aux exigences dans un délai de correction de 18 mois. Pendant ce temps, les actions RBOT continueront à être échangées avec une désignation '.BC' (en dessous des critères). Si le plan n'est pas soumis à temps ou accepté, la NYSE engagera une procédure de radiation.
L'avis n'affecte pas les opérations quotidiennes ni les obligations de reporting SEC. L'entreprise évalue des options pour retrouver la conformité avec les normes de cotation de la NYSE.
Vicarious Surgical (NYSE: RBOT) hat am 10. April 2025 eine Mitteilung von der NYSE erhalten, die auf die Nichterfüllung der Anforderungen für eine fortlaufende Listung hinweist. Das Unternehmen konnte sowohl eine 30-Tage-Durchschnittsmarktkapitalisierung als auch ein Eigenkapital der Aktionäre von über 50 Millionen Dollar nicht aufrechterhalten, wobei die Marktkapitalisierung durchschnittlich etwa 47,4 Millionen Dollar betrug.
Das Unternehmen hat 45 Tage, um einen Compliance-Plan bei der NYSE einzureichen, in dem die Maßnahmen zur Erfüllung der Anforderungen innerhalb eines 18-monatigen Heilungszeitraums dargelegt werden. Während dieser Zeit wird die RBOT-Aktie weiterhin mit einer '.BC'-Bezeichnung (unter den Kriterien) gehandelt. Wenn der Plan nicht rechtzeitig eingereicht oder akzeptiert wird, wird die NYSE ein Delisting-Verfahren einleiten.
Die Mitteilung hat keine Auswirkungen auf den täglichen Betrieb oder die Berichtspflichten gegenüber der SEC. Das Unternehmen prüft Optionen, um die Einhaltung der NYSE-Listingstandards wiederherzustellen.
- Company continues trading on NYSE during compliance period
- Business operations remain unaffected
- 18-month period granted to achieve compliance
- Market capitalization fell below $50M requirement to $47.4M
- Stockholders' equity below $50M threshold
- Risk of potential NYSE delisting if compliance plan fails
- Addition of '.BC' designation may negatively impact stock perception
Insights
The NYSE non-compliance notice represents a significant regulatory challenge for Vicarious Surgical. With the company's
This dual-trigger non-compliance is particularly concerning. The company must submit a credible compliance plan within 45 days, then would have 18 months to execute if approved. During this period, the stock will trade with a ".BC" (below criteria) designation, which typically creates additional market friction and can deter certain institutional investors from establishing or maintaining positions.
For early-stage medical robotics companies like Vicarious Surgical, maintaining NYSE listing requirements is especially challenging given their capital-intensive development cycles and pre-revenue status. The compliance gap appears relatively modest in numerical terms (
While the notice doesn't immediately affect operations, it introduces significant strategic complications. Capital raising activities—often essential for robotics development—become more challenging under non-compliance status. Management must now allocate resources toward addressing listing requirements while simultaneously advancing their core surgical robotics technology, creating potential operational distractions at a critical development stage.
As set forth in the Notice, as of April 9, 2025, the 30 trading-day average market capitalization was approximately
In accordance with applicable NYSE procedures, the Company has 45 days from the date the Notice was received to submit a plan advising the NYSE of the definitive action(s) the Company has taken, is taking, or plans to take to bring it into compliance with Section 802.01B within 18 months of receipt of the Notice. If the Company’s plan is not submitted on a timely basis or is not accepted, the NYSE will initiate delisting proceedings.
Pending NYSE acceptance of the plan, the Company’s Class A common stock will continue to be listed and traded on the NYSE during the 18-month cure period. Continued listing is also subject to the Company’s compliance with other applicable NYSE requirements and to quarterly NYSE review of the Company’s progress toward achieving compliance with the plan.
In the interim, the Company’s Class A common stock will continue to trade on the NYSE under the symbol “RBOT” with the designation of “.BC” to indicate the status of the shares as “below criteria,” but is otherwise not immediately impacted by the Notice. The “.BC” indicator will be removed at such time as the Company regains compliance.
The Notice also does not affect Securities and Exchange Commission reporting obligations by the Company.
The Company is considering all available options to regain compliance with the NYSE’s continued listing standards.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next-generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Vicarious Surgical’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the Company’s ability to develop a plan to regain compliance with the continued listing criteria of the NYSE; the NYSE’s acceptance of such plan; the Company’s ability to execute such plan and to continue to comply with applicable listing standards within the available cure period; risks arising from the potential suspension of trading of the Company’s Class A common stock on the NYSE; the approval, commercialization and adoption of Vicarious Surgical’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of Vicarious Surgical to raise financing in the future; the success, cost and timing of Vicarious Surgical’s product and service development activities; the potential attributes and benefits of Vicarious Surgical’s product candidates and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; Vicarious Surgical’s ability to identify, in-license or acquire additional technology; Vicarious Surgical’s ability to maintain its existing license, manufacture, supply and distribution agreements; Vicarious Surgical’s ability to compete with other companies currently marketing or engaged in the development of products and services that Vicarious Surgical is currently marketing or developing; the size and growth potential of the markets for Vicarious Surgical’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Vicarious Surgical’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; Vicarious Surgical’s financial performance; economic downturns, political and market conditions and their potential to adversely affect Vicarious Surgical’s business, financial condition and results of operations; Vicarious Surgical’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250411992350/en/
Investor Contact
Kaitlyn Brosco
Vicarious Surgical
Kbrosco@vicarioussurgical.com
Media Inquiries
media@vicarioussurgical.com
Source: Vicarious Surgical Inc.
FAQ
What caused Vicarious Surgical (RBOT) to receive NYSE delisting notice in April 2025?
How long does Vicarious Surgical (RBOT) have to resolve its NYSE listing compliance issues?
Will RBOT stock continue trading on NYSE after receiving the delisting notice?
What are the minimum NYSE listing requirements that RBOT must meet to maintain listing?
